Human Anti-CD28 x Anti-CSPG4 Bispecific Antibody (IgG-IgG) (BSIG-H237)

Anti-CD28 x Anti-CSPG4 Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD28 and anti-CSPG4 parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can retarget T cells to tumor cells. It is designed for the research of Melanoma therapy.

Datasheet INQUIRY

Specifications

Targets

CD28 & CSPG4

Type

IgG-IgG

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Melanoma

Targets

Target 1

CD28

Gene ID

940

UniProt ID

P10747

Alternative Names

CD28; CD28 molecule; Cluster of Differentiation 28; Tp44; T-cell-specific surface glycoprotein CD28; CD28 antigen

Target 2

CSPG4

Gene ID

1464

UniProt ID

Q6UVK1

Alternative Names

NG2; Neuron-glial antigen 2; Melanoma-associated chondroitin sulfate proteoglycan; chondroitin sulfate proteoglycan 4; CSPG4; MCSP; MCSPG; MSK16; HMW-MAA; MEL-CSPG

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Human Anti-CD28 x Anti-CSPG4 Bispecific Antibody (IgG-IgG) (BSIG-H237). Click the button below to contact us or submit your feedback about this product.

Human Anti-CD28 x Anti-CSPG4 Bispecific Antibody (IgG-IgG) (CAT#: BSIG-H237)

Specifications

Targets

Customer Reviews and Q&As